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This study examined the effect of experimentally
induced fever on the pharmacokinetics of cefepime
(75 mg/kg BW) administered intramuscularly to six
rabbits. The study was carried out in two consecutive
phases separated by a two-week washout period. An
infection was induced by an intravenous inoculation of
5 × 10
8 colony-forming units of Escherichia coli 24 h
before the pharmacokinetic investigation. A quantitative
microbiological assay was employed to measure the plasma
cefepime concentrations using an agar-gel diffusion
method with Bacillus subtilis ATCC 6633 as the test
organism. Twenty-four hour after the injection, the rectal
temperature in the infected animals increased by 1
oC.
There was a significant reduction in the elimination half-
life by 21.8% in the febrile rabbits compared to healthy
animals. In addition, the infection significantly increased
the peak plasma concentrations by 11.9%, the mean
residence time by 19.9%, the area under the plasma-
concentration-time curve by 53.6% and the area under
the moment curve by 62.3%. In conclusion, the
endotoxin-induced febrile state produced significant
changes in the plasma levels as well as some of the
pharmacokinetic variables of cefepime in rabbits.
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Introduction
Cefepime (a molecular formula of C 19H25ClN6O5S2HClH2O
and a molecular weight of 571.5) is a parenteral fourth-
generation cephalosporin antibiotic
 with a wide spectrum of
antimicrobial activity and a pharmacokinetic profile similar
to ceftazidime [18]. It is active
 against many Gram-positive
and Gram-negative bacteria, such as Staphylococcus aureus,
Streptococcus pneumoniae, Escherichia coli, Klebsiella
pneumoniae, Proteus mirabilis and Pseudomonas aeruginosa
[5,25], with less susceptibility to extended-spectrum-lactamases
[13]. The chemical structure of cefepime allows it to bind to
the penicillin-binding proteins and penetrate the outer
membrane of Gram-negative bacteria more rapidly than
most cephalosporins. In humans, cefepime has been
approved for the treatment of lower respiratory tract, intra-
abdominal, complicated and uncomplicated urinary tract
infections as well as uncomplicated skin and skin structure
infections [18]. It has also been shown to be therapeutically
equivalent to cefotaxime and ceftriaxone in the treatment of
pediatric meningitis [20].
Fever, which may be associated with many bacterial and
viral diseases, changes various physiological parameters
such as the heart rate, renal blood flow, hepatic and total
splanchnic blood flow, diuresis, and enzyme activities [14],
which can alter the pharmacokinetics of certain drugs [3].
For example, an increased volume of distribution for
penicillin-G has been reported in rabbits, pigs and dogs
during endotoxin-induced fever [26]. However, pigs, dogs
and rabbits showed higher blood concentrations of sulphathiazole,
sulphadimidine and gentamicin during endotoxin-induced
fever [26]. Therefore, animals suffering from fever may
require a modified dose regimen.
The pharmacokinetics of cefepime have previously been
examined in monkeys and rats [7], adult horses [10], dogs
[8,24], neonatal foals [8] calves [11] and ewes [12]. However,
there is little information of the pharmacokinetics of
cefepime after administration via the intramuscular route,
which is the most popular and convenient route of administration.
Rabbits are quite prone to abscesses formation and
respiratory diseases. The bacteria most often involved in
these complications include Pasteurella multocida and
Staphylococcus aureus. However, there are few antibiotics
that can provide a safe and effective therapy for such
conditions particularly those caused by resistant strains.
Cefepime can be used to treat bacterial infections caused by
strains resistant to other antibiotics. Furthermore, animals
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suffering from fever may require a modified dosage
regimen. Therefore, the main objective of this study was to
determine the effects of experimentally induced fever on the
disposition kinetics of cefepime administered intramuscularly to
rabbits. The dose used in this experimental model is somewhat
lower than that used in previous studies in a meningitis
model [9].
Materials and Methods
Antimicrobial agent administration
Cefepime hydrochloride powder (Maxipime; Bristol-Meyers
Squibb, USA) was reconstituted with sterile normal saline to
a final concentration of 10% according to the manufacturer’s
guidelines, and was administered intramuscularly to healthy
and febrile rabbits at a dose of 75 mg/kg BW.
Animals and husbandry
The study was performed in accordance with the guidelines
for animal care of the Faculty of Veterinary Medicine, Cairo
University, Egypt. Six healthy male rabbits, weighing 2,100-
2,500 g, were obtained from the Laboratory Animal Farm,
Faculty of Veterinary Medicine, Cairo University, Egypt.
The rabbits were housed individually in cages under a 12-h
light/dark cycle and fed good quality hay (alfalfa) and/or a
pelleted feed concentrate (fiber 18%, protein 14%, calcium
>1 and fat 2%) with free access to water. The room temperature
and relative humidity were maintained at 20 and 22
oC, and
between 30 and 60%, respectively. The animals were allowed
to acclimatize and did not receive any drug treatment for at
least 15 days preceding the study. The same rabbits were
used in subsequent experiments after observing a minimum
washout period of 2 weeks.
Experimental protocol
The study comprised of the following 2 phases:
Phase 1: The animals were individually weighed immediately
be administering the drug in order to determine the precise
dose. Prior to the intramuscular injection, each rabbit was
placed in a restraining device. All the rabbits were injected
with freshly prepared cefepime (75 mg/kg BW) into the left
semimembranous muscle. Heparinized blood samples (0.5
ml) were obtained from the right auricular vein. Blood
samples were collected immediately before (pre-treatment,
0 h) and 10, 20, 30, 45 min as well as 1, 2, 4, 6, 8, 10, 12, 24,
and 48 h after drug administration. Each blood sample was
gently inverted a few times in order to allow for complete
mixing with the anticoagulant and stored on ice. Within
30 min of collection, each sample was centrifuged for
15 min at approximately 1,500 × g to separate the plasma.
The plasma samples were stored in −20°C, and assayed on
the same day of sampling.
Phase 2: The clinically isolated E. coli strains (obtained
from Department of Microbiology, Faculty of Veterinary
Medicine, Cairo University, Egypt) were stored at −80
oC
until needed. These strains were recovered by inoculating a
small portion of the stock into heart infusion agar (Difco,
USA) overnight at 37
oC to obtain logarithmic-phase growth.
A single colony was selected and suspended in a pyrogen-
free phosphate buffered solution. The concentrations of
bacteria after the overnight culture were estimated from the
optical density as well as by serial dilution. This suspension
was then diluted to achieve a concentration of 10
7~10
8
colony-forming units (CFU)/ml. An infection was induced
by an intravenous inoculation of 5×10
8 CFU, 24 h before the
pharmacokinetic investigation. Cefepime was administered
intramuscularly at the same dose and the sampling procedures
were performed as in phase 1.
Analytical method
The plasma cefepime concentrations were determined
using a microbiological assay method
 described elsewhere
[2,17], with Bacillus subtilis ATCC 6633 as the indicator
strain growing on Mueller-Hinton agar (Mast Group, UK).
Briefly,  six wells, 8 mm in diameter, were cut at equal
distances into a (120 × 120 mm) petri plate containing 25 ml
of seeded agar. The wells were filled with the test samples
and/or  a  cefepime standard solution (prepared from a
commercial solution). Standard curve of cefepime was
prepared in pooled antibacterial-free plasma. The standards
and samples were tested in duplicate. The plates were kept
at room temperature for 2 h before being incubating at 37
oC
for 18 h. The mean inhibition zone diameters were
measured and the concentrations in the plasma samples
were calculated from the standard curve. The standards were
included in each assay plate in order to compensate for any
plate-to-plate variations. There was a linear relationship
between the zone of inhibition and the logarithm of the
plasma cefepime concentration with a correlation coefficient
of 0.990. The intra-day coefficient of variation was <8%.
The reproducibility of this method was excellent and the
inter-assay variability was <5%. The limit of quantitation was
0.1 µg/ml. A standard curve was considered acceptable if
the quality control samples were within 15% of the nominal
concentration. This assay failed to distinguish between
cefepime and its antibacterial metabolite(s). Therefore,
results are expressed as the plasma cefepime equivalent
activity. However, in order to simplify the presentation, the
term, concentrations, are used throughout the text.
Pharmacokinetic analysis
The pharmacokinetic parameters of cefepime were estimated
by noncompartmental method using WinNonlin V2.0
(Pharsight, USA). The rate constant associated with the log/
linear part of the curve (λ) was determined using linear
regression. The total area under the plasma concentration-
time curve (AUC) was calculated using the linear trapezoidal
rule. The AUC from 0 to infinity [AUC 0~∞] was calculated asFever alters the disposition of cefepime in rabbits 153
the AUC (0, ∞) = AUC + Ct/λ (where Ct is the last plasma
concentration measured). The elimination half-life (t1/2λ) of
cefepime was calculated using the following equation: t1/2λ=ln 2/λ.
Statistical analysis
The results are expressed as the mean ± SD. The differences
in the pharmacokinetic values obtained before and after the
infection were compared using a paired t-test (two-tailed).
All the data was analyzed using the statistical program,
Sigmastat (version 2.0; SPSS, USA). The differences were
considered statistically significant at p < 0.05.
Results
Response to infection and drug
The intravenous inoculation of 5 × 10
8 CFU of Escherichia
coli  caused an increase in body temperature. Twenty-four
hour after the injection, the temperature increased to 1.0
oC
above the basal value. With the exception of mild anorexia,
there were no abnormal findings of appearance in the infected
rabbits, such as corneal hyperemia or increased lassitude.
No serious adverse events of cefepime were observed
throughout the study. Most animals experienced none to
mild pain and only minimal discomfort at the injection site.
Pharmacokinetic analysis
The standard curve for cefepime in plasma was linear
within the concentration ranges of 0.1 to 200 µg/ml. Table 1
shows the mean plasma concentration-time data of cefepime
after intramuscular administration in rabbits before and after
the infection. The infection caused a marked increase in the
plasma cefepime concentration from 0.166 to 24 h after
administration, with the exception of 0.5 h. The drug was
not detected in the plasma 48 h after drug administration
(Table 1). Table 2 shows the pharmacokinetic parameters .
There was a significant decrease in the elimination half-life
(p = 0.002) compared with healthy animals. In addition, the
infection significantly increased the peak plasma concentrations
(p = 0.022), the mean residence time (p = 0.002), the area
under the plasma-concentration time curve (p < 0.0001) and
the area under the moment curve (p = 0.0001).
Discussion
The interpretation of the data considered the assay method
used (microbiological) and the sensitivity of the assay
method. This is because cefepime and its putative metabolites
might have different antimicrobial activities, the ratio of the
parent to its metabolites might not remain constant throughout
the dosing interval and the movement of the metabolites
from the blood may not be the same as for the parent drug.
Therefore, there might be some error in interpreting the
concentrations derived from the microbiological assay for
the purpose of establishing minimally effective concentrations
in plasma. The bioassay method was chosen because of cost
constraints and that other researchers have reported non-
significant differences between the results of the microbiological
assay and HPLC methods [17]. On the other hand, Bächer  et
al. [2], reported a good correlation coefficient between the
HPLC and the bioassay in human serum (r = 0.950), but
only presented the data from the bioassay method.
The intravenous inoculation of the E.coli suspension into
the rabbits simulates some of the pathological effects of
septicemia in humans [31]. The increase in body temperature,
cardiac and respiratory rate and peripheral resistance are
followed by secondary acidosis and decreases in cardiac
output. These rheological alterations correspond to the
changes in circulation observed in septicemic humans [22].
Table 1. Plasma concentrations of cefepime after intramuscular administration to healthy and febrile rabbits
(n = 6, unit: µg/ml, mean ± SD)
Time (h) Healthy Febrile p-value
00.00 00.0 ± 0.000 0.0 ± 0.0 0.0
000.166 39.97 ± 4.110 49.82 ± 4.87 0.03
00.33 76.99 ± 4.030 95.88 ± 4.22 0.0004
0.5 114.93 ± 9.5100 126.26 ± 4.840 0.081
00.75 95.73 ± 6.090 128.25 ± 7.380 <0.0001
1.0 64.24 ± 9.040 120.74 ± 6.240 <0.0001
2.0 46.81 ± 4.970 91.87 ± 5.23 <0.0001
4.0 25.03 ± 1.750 61.45 ± 5.87 <0.0001
6.0 13.12 ± 1.930 38.45 ± 3.19 <0.0001
8.0 7.66 ± 1.25 23.49 ± 0.71 <0.0001
10.00 4.11 ± 1.23 14.48 ± 0.83 <0.0001
12.00 2.68 ± 0.81 08.73 ± 1.42 0.0006
24.00 0.31 ± 0.02 00.63 ± 0.13 0.0006
48.00 ND ND -
ND: not detected , Wilcoxon test was applied to sampling time (0.166 h)154 Ayman Goudah et al.
Furthermore, the changes in the acid-base balance also
influence the physicochemical properties of cephalosporins.
The changes in pH lead to sigmoidal changes in the degree
of ionization, which in turn leads to changes in the mean
residence time [21,29].
The acute phase response (APR) is defined as a
pathophysiological condition induced by many causal
factors, i.e. infection, inflammation and tissue. The APR
induces many systemic changes, which include fever,
increased lassitude, loss of appetite as well as the synthesis
and secretion of acute phase hepatic proteins [27]. Significant
concentrations of proinflammatory cytokines, such as tumor
necrosis factor-α, interleukins and interferons, are produced
during APR, which leads to the direct suppression of the
microsomal cytochrome P450 (CYP)-dependent activity in
the liver [1,4,30]. This might in turn alter the pharmacokinetic
profile of the some drug. Furthermore, studies in experimental
animals have shown that the maximum depression of CYP
occurs 12~24 h after an LPS injection [15]. Cephalosporins
have neither inhibitory nor stimulatory effects [16]. Therefore,
the decreases in the elimination of cefepime in the infected
rabbits might be related to the suppression of the CYP
isoforms by the microbial suspension.  The process of
enzyme inhibition usually begins with the first dose of the
inhibitor, and the onset and offset of inhibition correlate with
the half-lives of the drugs used [6]. Similar findings of a
decrease in elimination had been reported for theophylline
and phenytoin in humans during APR as follows: a decrease
of theophylline elimination due to a viral respiratory
infection [3], bacterial pneumonia [23,28] and influenza
vaccine inoculation [19]. There are few reports on the in
vivo metabolism of cefepime in animals. In humans,
cefepime is metabolized to N-methylpyrrolidine (NMP),
which is rapidly converted to the N-oxide (NMP-N-oxide).
To our knowledge, there is no evidence of the production of
active metabolites in rabbits.
The significantly higher AUC, area under first moment of
plasma concentration-time curve and mean residence time
values in febrile rabbits observed in this study show that the
drug remains in the body for a comparatively longer
duration in the febrile condition.
In conclusion, the cefepime dose used in this study
produced therapeutically useful concentrations in the plasma.
The endotoxin-induced febrile state produced significant
changes in the plasma levels and some of the pharmacokinetic
variables of cefepime. Nonetheless, these changes are not
likely to adversely affect the desirable properties of cefepime
in rabbits.
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